| scholarly article | Q13442814 |
| P50 | author | Ruth Nussenzweig | Q2177773 |
| P2093 | author name string | Quakyi, I.A. | |
| Zavala F | |||
| Hollingdale MR | |||
| Nussenzweig V | |||
| Cochrane AH | |||
| Tam JP | |||
| Hollingdale, M.R. | |||
| Quakyi I | |||
| Cochrane, A.H. | |||
| Nussenzweig, R.S. | |||
| Nussenzweig, V. | |||
| Tam, J.P. | |||
| Zavala, F. | |||
| P433 | issue | 4706 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| vaccine | Q134808 | ||
| Plasmodium falciparum malaria | Q18554672 | ||
| Plasmodium falciparum | Q311383 | ||
| malaria vaccine | Q6741353 | ||
| peptide | Q172847 | ||
| P304 | page(s) | 1436-1440 | |
| P577 | publication date | 1985-01-01 | |
| 1985-06-01 | |||
| P1433 | published in | Science | Q192864 |
| P1476 | title | Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria | |
| P478 | volume | 228 |
| Q52350559 | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. |
| Q52596481 | A new site of attack for a malaria vaccine. |
| Q42772638 | A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines |
| Q34734075 | A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. |
| Q53700367 | A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. |
| Q44146077 | A rapid inhibition micro ELISA for detecting antibodies to Plasmodium falciparum sporozoites in human blood |
| Q34889790 | A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys |
| Q21034112 | A review of malaria vaccine clinical projects based on the WHO rainbow table |
| Q47887725 | A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. |
| Q36668561 | Active and passive immunization against Plasmodium yoelii sporozoites |
| Q47879434 | Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes. |
| Q34700810 | Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice |
| Q44909377 | An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion |
| Q33830488 | An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses |
| Q38635546 | An update on candidate malaria vaccines |
| Q40484421 | Antibodies to the Circumsporozoite Protein and Protective Immunity to Malaria Sporozoites |
| Q34530938 | Antibody and B cell responses to Plasmodium sporozoites |
| Q45215361 | Antibody responses to a synthetic peptide-based malaria vaccine candidate: influence of sequence variants of the peptide |
| Q91900073 | Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine |
| Q59793166 | Antibody-Mediated Protection against Sporozoites Begins at the Dermal Inoculation Site |
| Q35946430 | Antigenic diversity and immune evasion by malaria parasites. |
| Q40489535 | Antigenicity and immunogenicity of antigenized antibodies. Studies on B and T cells |
| Q39447157 | Antigens of Plasmodium falciparum blood stages with clinical interest cloned and expressed in E. coli |
| Q40213540 | Assay for detection of Trypanosoma cruzi antibodies in human sera based on reaction with synthetic peptides |
| Q68231229 | Assay, purification and characterization of a recombinant malaria circumsporozoite fusion protein by high-performance liquid chromatography |
| Q47903948 | Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum |
| Q34704130 | Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children |
| Q37483705 | CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites |
| Q40429530 | Characterization and vaccine potential of a novel recombinant coccidial antigen. |
| Q28304173 | Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens |
| Q40193241 | Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection |
| Q90403559 | Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein |
| Q41194352 | Circumsporozoite antibodies and falciparum malaria incidence in children living in a malaria endemic area |
| Q35063553 | Circumsporozoite protein of Plasmodium berghei: gene cloning and identification of the immunodominant epitopes |
| Q46629754 | Circumvention of MHC class II restriction by genetic immunization |
| Q36780612 | Cloning and sequencing of a cDNA fragment from Plasmodium chabaudi chabaudi that contains repetitive sequences coding for a potentially lysine-rich aspartic acid-rich protein |
| Q41200913 | Comparative analysis of ELISAs employing repetitive peptides to detect antibodies to Plasmodium falciparum sporozoites |
| Q39649775 | Conformational restriction of peptidyl immunogens with covalent replacements for the hydrogen bond |
| Q47303165 | Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective. |
| Q47911136 | Construction of immunogens for synthetic malaria vaccines |
| Q47896240 | Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate |
| Q57479092 | Cryo-EM structure of circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts |
| Q59387720 | Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin |
| Q95816309 | DNA fingerprinting |
| Q89621117 | Detection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute Plasmodium falciparum Malaria |
| Q37134841 | Detection of human antibodies against Plasmodium falciparum sporozoites using synthetic peptides |
| Q40207828 | Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32). |
| Q38872073 | Development of whole sporozoite malaria vaccines |
| Q47865483 | Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate |
| Q40715913 | Developments with anti-malarial vaccines. |
| Q39413199 | Distribution of repetitive and non-repetitive circumsporozoite protein epitopes on Plasmodium falciparum sporozoites and immunochemical characterization of human malaria antisera |
| Q92296514 | Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein |
| Q46792025 | Durable immunity and immunologic memory to a parasite antigen induced by somatic transgene immunization |
| Q41200573 | ELISA method for detecting Plasmodium falciparum circumsporozoite antibody |
| Q43583421 | Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques |
| Q40159003 | Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites |
| Q47888732 | Effect of priming with carrier on response to conjugate vaccine |
| Q40754536 | Engineered human vaccines |
| Q46037794 | Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes. |
| Q42993636 | Experimental vaccination of chicks with Plasmodium gallinaceum sporozoites. I. Circumsporozoite proteins are expressed by sporozoites recovered from both salivary glands and midguts of mosquitoes |
| Q36353517 | Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine |
| Q51806092 | Expression of trypomastigote trans-sialidase in metacyclic forms of Trypanosoma cruzi increases parasite escape from its parasitophorous vacuole. |
| Q55455387 | Expression profiling of Trypanosoma congolense genes during development in the tsetse fly vector Glossina morsitans morsitans. |
| Q38189681 | Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity |
| Q35662378 | Flow Cytometry Based Detection and Isolation of Plasmodium falciparum Liver Stages In Vitro |
| Q31152863 | Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities |
| Q36352284 | Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine |
| Q37911988 | Genetic diversity in Plasmodium falciparum |
| Q48004274 | Genetic restriction and specificity of the immune response in mice to fusion proteins containing repeated sequences of the Plasmodium falciparum antigen Pf155/RESA. |
| Q48051980 | Genetic restriction in two conserved regions of Plasmodium falciparum EBA-1751t |
| Q33646573 | High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria |
| Q92827824 | Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein |
| Q44643587 | Identification of epitopes within the circumsporozoite protein of Plasmodium vivax recognized by murine T lymphocytes |
| Q36702125 | Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites |
| Q40259888 | Immune Responses in Malaria |
| Q38884318 | Immune responses to multiple antigen peptides containing T and B epitopes from Plasmodium falciparum circumsporozoite protein of Brazilian individuals naturally exposed to malaria |
| Q46195416 | Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization |
| Q36363602 | Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes |
| Q35005868 | Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine |
| Q41252284 | Immunogenicity of a non-repetitive sequence of Plasmodium falciparum circumsporozoite protein in man and mice. |
| Q37521191 | Immunogenicity of an engineered internal image antibody |
| Q42114064 | Implications from predicted B-cell and T-cell epitopes of Plasmodium falciparum merozoite proteins EBA175-RII and Rh5. |
| Q34373653 | In vivo testing of subunit vaccines against malaria sporozoites using a rodent system |
| Q41825440 | Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria |
| Q35156887 | Insights into the trypanosome-host interactions revealed through transcriptomic analysis of parasitized tsetse fly salivary glands |
| Q36773737 | Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy |
| Q40157659 | Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen |
| Q58569727 | Malaria prevention: from immunological concepts to effective vaccines and protective antibodies |
| Q37657392 | Malaria vaccine |
| Q45883531 | Malaria vaccine: the latest news from RTS,S/AS01E vaccine |
| Q41739876 | Molecular basis for evasion of host immunity and pathogenesis in malaria |
| Q24798369 | Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor |
| Q37657385 | Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis |
| Q37118222 | Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity |
| Q34290800 | Multiple Antigen Peptide Vaccines againstPlasmodium falciparumMalaria |
| Q47864161 | Multiple antigen peptides for specific detection of antibodies to a malaria antigen in human sera |
| Q47921163 | Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria |
| Q33599748 | Natural antibody responses against the non-repeat-sequence-based B-cell epitopes of the Plasmodium falciparum circumsporozoite protein |
| Q38715960 | Nature and nurture: overcoming constraints on immunity |
| Q47863134 | New B cell epitopes in thePlasmodium falciparum malaria circumsporozoite protein |
| Q38715974 | Non-linear phenomena in host-parasite interactions |
| Q35561160 | P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections |
| Q67657912 | Peptide Immunogen Mimicry of a Protein-Specific Structural Epitope on Human Choriogonadotropin |
| Q34462075 | Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites |
| Q40876140 | PhiXing-it, displaying foreign peptides on bacteriophage ΦX174. |
| Q37028297 | Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. |
| Q39731068 | Plasmodium falciparum antigens as target molecules for a protective immunization against malaria: an up-to-date review |
| Q47887602 | Plasmodium falciparum circumsporozoite (CS) protein peptides specifically bind to HepG2 cells. |
| Q47830000 | Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. |
| Q34416103 | Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates |
| Q47853144 | Potentiation of immune response against the RESA peptides of Plasmodium falciparum by incorporating a universal T-cell epitope (CS.T3) and an immunomodulator (polytuftsin), and delivery through liposomes |
| Q37392892 | Predicted conformations for the immunodominant region of the circumsporozoite protein of the human malaria parasite Plasmodium falciparum |
| Q37001511 | Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. |
| Q36024455 | Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies |
| Q90214251 | RTS,S/AS01 vaccine (Mosquirix™): an overview |
| Q35590960 | Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion |
| Q47372765 | Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection |
| Q38665423 | Rationale for the development of an engineered sporozoite malaria vaccine |
| Q38560128 | Recent advances in the development of a chemically synthesised anti-malarial vaccine |
| Q46273301 | Repetitive sequences in malaria parasite proteins. |
| Q70233009 | Reversed-phase liquid chromatography and sodium dodecyl sulfate polyacrylamide gel electrophoresis characteristics of a recombinant DNA derived malaria antigen |
| Q34156866 | Ribosome display of combinatorial antibody libraries derived from mice immunized with heat-killed Xylella fastidiosa and the selection of MopB-specific single-chain antibodies |
| Q48001511 | Selection of carrier and B cell protectope sequences for vaccines |
| Q40669205 | Sensitive and specific DNA probe for detection of Plasmodium falciparum |
| Q39075264 | Steps towards a malaria vaccine |
| Q47161602 | Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein |
| Q90160111 | Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein |
| Q43468469 | Studies on glycoproteins in the human malaria parasite Plasmodium falciparum. Identification of a myristilated 45kDa merozoite membrane glycoprotein |
| Q42826894 | Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei |
| Q43462014 | Study on the natural history of malaria in areas of the Rondonia State-Brazil and problems related to its control |
| Q38665396 | Synthetic T and B cell recognition sites: implications for vaccine development |
| Q34602484 | Synthetic gene construct expressing a repeated and highly immunogenic epitope of the Plasmodium falciparum antigen Pf155. |
| Q36357591 | Synthetic peptide vaccine confers protection against murine malaria |
| Q42938628 | Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro |
| Q41349538 | T-dependent B cell responses to Plasmodium induce antibodies that form a high-avidity multivalent complex with the circumsporozoite protein. |
| Q44888648 | The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity |
| Q37611985 | The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines |
| Q30531039 | The all pervasive principle of repetitious recurrence governs not only coding sequence construction but also human endeavor in musical composition |
| Q47900224 | The challenge of malaria vaccine: trials and tribulations |
| Q36650703 | The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? |
| Q35555731 | The development of subunit and synthetic vaccines using recombinant DNA technology |
| Q36799301 | The efficiency of sporozoite transmission in the human malarias, Plasmodium falciparum and P. vivax |
| Q37012062 | The immunological challenges of malaria vaccine development |
| Q44397744 | The malaria vaccine candidate RTS,S/AS is in phase III clinical trials |
| Q45157941 | The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen |
| Q35180010 | Theoretical and Practical Aspects of Antigenized Antibodies |
| Q34634916 | Theoretically determined three-dimensional structure for the repeating tetrapeptide unit of the circumsporozoite coat protein of the malaria parasite Plasmodium falciparum |
| Q27026412 | Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites |
| Q36787013 | Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an N-terminally anchored integral membrane protein |
| Q67665882 | Use of Prior Vaccinations for the Development of New Vaccines |
| Q44462515 | Use of commercial anion-exchange resins as solid support for peptide synthesis and affinity chromatography |
| Q37622906 | Use of hepadnavirus core proteins as vaccine platforms |
| Q47878399 | VH and VL region structure of antibodies that recognize the (NANP)3 dodecapeptide sequence in the circumsporozoite protein of Plasmodium falciparum |
| Q36117148 | Vaccination against malaria |
| Q42126049 | Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum |
| Q34119885 | Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice |
| Q28742277 | Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children |
| Q36636738 | Where Are We in the Quest for Vaccines for Malaria? |
| Q48030409 | Within-population genetic diversity of Plasmodium falciparum vaccine candidate antigens reveals geographic distance from a Central sub-Saharan African origin. |
Search more.